FLAB-PSPA |
|
Vaxjo ID |
304 |
|
Vaccine Adjuvant Name |
FLAB-PSPA |
|
Adjuvant VO ID |
VO_0005270
|
|
Description |
Flagellin (FlaB) is a Toll-like receptor 5 (TLR5) activator, and it is used as a mucosal adjuvant. Pneumococcal surface protein A (PspA) is a bacterial surface protein from *Streptococcus pneumoniae* used as an antigen. |
|
Stage of Development |
Research |
|
Host Species for Testing |
Rat |
|
Components |
flagellin (FlaB)-dependent Toll-like receptor 5 (TLR5) |
|
Structure |
The paper mentions a "FlaB-PspA fusion protein" but does not detail its specific molecular structure. |
|
Function |
The FlaB-PspA fusion protein induced a significantly higher level of PspA-specific IgG and IgA responses and demonstrated a high protective efficacy against a lethal challenge with live S. pneumoniae in aged mice. These results suggest that caveolin-1/TLR5 signaling plays a key role in age-associated innate immune responses and that FlaB-PspA stimulation of TLR5 may be a new strategy for a mucosal vaccine adjuvant against pneumococcal infection in the elderly. |
|
Safety |
The study demonstrated that the FlaB-PspA fusion protein provided "high protective efficacy against a lethal challenge with live S. pneumoniae in aged mice," indicating a positive outcome in the animal model. Specific safety data on adverse effects or human trials are not provided. |
| Related Vaccine(s) |
|
| References |
Lim et al., 2015: Lim JS, Nguyen KC, Nguyen CT, Jang IS, Han JM, Fabian C, Lee SE, Rhee JH, Cho KA. Flagellin-dependent TLR5/caveolin-1 as a promising immune activator in immunosenescence. Aging cell. 2015; 14(5); 907-915. [PubMed: 26223660].
|
